Merus NV (NASDAQ:MRUS) has been given a consensus rating of “Hold” by the nine research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $24.00.
Several equities research analysts recently weighed in on the stock. Berenberg Bank reduced their price objective on shares of Lucara Diamond from C$1.60 to C$1.50 in a report on Wednesday, March 27th. BidaskClub raised shares of Zogenix from a “sell” rating to a “hold” rating in a report on Thursday, May 9th. Royal Bank of Canada set a €5.70 ($6.63) price objective on shares of Banco Santander and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Citigroup downgraded shares of Biogen from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $470.00 to $230.00 in a report on Thursday, March 21st. Finally, Roth Capital upped their price objective on shares of Franklin Covey from $34.00 to $40.00 and gave the stock a “buy” rating in a report on Friday, June 28th.
A number of institutional investors have recently modified their holdings of the business. Morgan Stanley raised its position in Merus by 74.3% in the third quarter. Morgan Stanley now owns 71,643 shares of the biotechnology company’s stock worth $1,415,000 after acquiring an additional 30,538 shares in the last quarter. Granite Investment Partners LLC bought a new stake in Merus in the first quarter worth about $468,000. Geode Capital Management LLC raised its position in Merus by 18.8% in the fourth quarter. Geode Capital Management LLC now owns 14,987 shares of the biotechnology company’s stock worth $209,000 after acquiring an additional 2,373 shares in the last quarter. Finally, Squarepoint Ops LLC raised its position in Merus by 10.3% in the fourth quarter. Squarepoint Ops LLC now owns 11,800 shares of the biotechnology company’s stock worth $165,000 after acquiring an additional 1,100 shares in the last quarter. Hedge funds and other institutional investors own 52.13% of the company’s stock.
Merus (NASDAQ:MRUS) last announced its quarterly earnings results on Thursday, May 30th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.22. The company had revenue of $8.75 million during the quarter, compared to the consensus estimate of $7.47 million. Merus had a negative net margin of 75.71% and a negative return on equity of 39.46%. Research analysts forecast that Merus will post -1.9 earnings per share for the current year.
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
See Also: What is Cost of Capital?
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.